Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Incannex Healthcare Ltd ADR (IXHL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: IXHL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -47.52% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.05M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.47 | 52 Weeks Range 0.08 - 3.12 | Updated Date 06/29/2025 |
52 Weeks Range 0.08 - 3.12 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.23 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -20952.04% |
Management Effectiveness
Return on Assets (TTM) -76.74% | Return on Equity (TTM) -201.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14183550 | Price to Sales(TTM) 194.37 |
Enterprise Value 14183550 | Price to Sales(TTM) 194.37 | ||
Enterprise Value to Revenue 144.73 | Enterprise Value to EBITDA -5.13 | Shares Outstanding 93695400 | Shares Floating 28234076 |
Shares Outstanding 93695400 | Shares Floating 28234076 | ||
Percent Insiders 26.14 | Percent Institutions 8.29 |
Upturn AI SWOT
Incannex Healthcare Ltd ADR
Company Overview
History and Background
Incannex Healthcare Ltd is an Australian pharmaceutical company focused on developing unique medicinal cannabis pharmaceutical products and psychedelic therapies for unmet medical needs. Founded in 2015, Incannex has focused on cannabinoid and psychedelic pharmaceutical development.
Core Business Areas
- Medicinal Cannabis: Development of cannabinoid-based pharmaceuticals to treat conditions like sleep apnea, traumatic brain injury, and inflammatory bowel disease.
- Psychedelic Therapies: Development of psychedelic therapies to treat anxiety disorders and other mental health conditions.
- Novel Drug Delivery: Focuses on innovative drug delivery systems to improve drug efficacy and patient outcomes.
Leadership and Structure
The company is led by a management team with experience in pharmaceuticals, biotechnology, and drug development. The organizational structure consists of research and development, clinical trials, and commercialization teams.
Top Products and Market Share
Key Offerings
- IHL-42X (Sleep Apnea): A proprietary cannabinoid formulation under development for obstructive sleep apnea. No current market share. Competitors: ResMed, Philips Respironics.
- PsiGAD (Generalized Anxiety Disorder): A psychedelic-assisted psychotherapy program utilizing psilocybin for the treatment of Generalized Anxiety Disorder. Early stages of clinical trials, no market share yet. Competitors: COMPASS Pathways, MindMed.
- IHL-675A (Inflammatory Disease): A compound in development for inflammatory diseases, consisting of cannabidiol (CBD) and hydroxychloroquine. No current market share. Competitors: Johnson & Johnson, AbbVie
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in the medicinal cannabis and psychedelic sectors, is experiencing rapid growth driven by increasing acceptance and regulatory changes. The industry is highly competitive and subject to stringent regulations.
Positioning
Incannex Healthcare Ltd is positioned as an innovator in medicinal cannabis and psychedelic therapies, targeting unmet medical needs with unique formulations and delivery systems. Their competitive advantage lies in their proprietary intellectual property and focus on clinical validation.
Total Addressable Market (TAM)
The combined TAM for medicinal cannabis and psychedelic therapies is estimated to be in the billions of dollars. Incannex aims to capture a significant portion of this market through its clinical development programs and commercialization efforts.
Upturn SWOT Analysis
Strengths
- Proprietary intellectual property
- Focus on unmet medical needs
- Experienced management team
- Strong clinical development pipeline
Weaknesses
- Limited revenue generation
- Dependence on capital raising
- High research and development costs
- Regulatory uncertainty
Opportunities
- Expanding regulatory acceptance of medicinal cannabis and psychedelics
- Increasing demand for alternative therapies
- Strategic partnerships and collaborations
- Potential for breakthrough therapies
Threats
- Competition from established pharmaceutical companies
- Changing regulatory landscape
- Clinical trial failures
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- GWPH
- CMPS
- MMEDF
Competitive Landscape
Incannex Healthcare Ltd faces competition from established pharmaceutical companies and other emerging players in the medicinal cannabis and psychedelic spaces. Its competitive advantage lies in its novel drug formulations and intellectual property. However, larger competitors have greater resources and established market presence.
Major Acquisitions
APIRx Pharmaceutical USA, LLC
- Year: 2022
- Acquisition Price (USD millions): 93.3
- Strategic Rationale: Acquisition of APIRx provides Incannex access to a portfolio of novel cannabinoid and synthetic cannabimimetic molecules, expanding their product pipeline.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of the clinical development pipeline and preclinical research. Revenue growth has been limited.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of products. Analyst estimates vary widely based on these factors.
Recent Initiatives: Recent initiatives include advancing clinical trials for IHL-42X and PsiGAD, expanding research collaborations, and seeking regulatory approvals.
Summary
Incannex Healthcare is a high-risk, high-reward pharmaceutical company focused on cannabinoid and psychedelic therapies. The company's strength lies in its novel drug formulations, experienced management, and focus on unmet medical needs. It faces risks associated with clinical trials, regulatory hurdles, and competition. Successful clinical trials will be the biggest catalyst to see revenue in the future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The pharmaceutical industry is subject to rapid change and regulatory uncertainty. Past performance is not indicative of future results. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Incannex Healthcare Ltd ADR
Exchange NASDAQ | Headquaters Sydney, NSW, Australia | ||
IPO Launch date 2022-03-02 | President, CEO & Executive Director Mr. Joel Bradley Latham | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 9 | Website https://www.incannex.com |
Full time employees 9 | Website https://www.incannex.com | ||
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.